← All trials
NCT04690387
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 7, 2020
- Primary completion
- Jan 31, 2021
- Completion date
- Jan 31, 2022
- First posted
- Dec 30, 2020
- Last posted
- Dec 30, 2020
- Enrollment
- 27
- Arms / groups
- 9 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AiVita Biomedical, Inc.Lead sponsor
- AiVita Biomedical, Inc.Study chair
- Government of IndonesiaCollaborator
- AiVita Biomedical, Inc.Collaborator
- Government of IndonesiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.